sglt2 inhibitors vs glp 1 Comparative effectiveness of inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records SGLT-2 inhibitors or GLP-1 receptor

A 20% relative risk reduction in MACE, including myocardial infarction, stroke, and cardiovascular death and a 30% relative risk reduction in hospitalizations for HF ( The VERTIS trial, involving 8246 patients with T2DM, compared ertugliflozin 5 mg or 15 mg daily to placebo for 3.5 years

Solid engineering prevents lag, sensible promos reward participation, and clear rules reduce confusion

Introduction to GLP-1 Agonists Glucagon-like peptide-1 (GLP-1) agonists are a class of medications that have gained significant attention in recent years for their ability to manage blood sugar levels and promote weight loss

We also believe in the value of whole-food support and working with supplements responsibly

Tanzeum [package insert]